Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$8.2M
Filings
144
Firms Hired
4
Active Period
2007–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Women and Lung Cancer Research and Preventive Services Act of 2025
2026 · third_quarter · Firm: DAIICHI SANKYO INC
Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions regarding H.R.4299,the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to most-favored-nation and other foreign reference drug pricing policy Issues related to the Food and Drug Administration Issues regarding 340B program Issues related to utilization management of medications
Client expense: $370,000 · Firm income: —
Matched citations: H.R.2319
Protecting Patient Access to Cancer and Complex Therapies Act
2026 · third_quarter · Firm: DAIICHI SANKYO INC
Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions regarding H.R.4299,the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to most-favored-nation and other foreign reference drug pricing policy Issues related to the Food and Drug Administration Issues regarding 340B program Issues related to utilization management of medications
Client expense: $370,000 · Firm income: —
Matched citations: H.R.4299
Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions regarding H.R.4299,the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to most-favored-nation and other foreign reference drug pricing policy Issues related to the Food and Drug Administration Issues regarding 340B program Issues related to utilization management of medications
Client expense: $370,000 · Firm income: —
Matched citations: H.R.946
Protecting Patient Access to Cancer and Complex Therapies Act
2026 · third_quarter · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340B program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act
2026 · third_quarter · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Women and Lung Cancer Research and Preventive Services Act of 2025
2026 · second_quarter · Firm: DAIICHI SANKYO INC
Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions related to the Protecting Patient Access to Cancer and Complex Therapies Act reintroduction Issues related to most-favored-nation and other foreign reference drug pricing policy Issues related to the Food and Drug Administration Issues regarding 340B program
Client expense: $380,000 · Firm income: —
Matched citations: H.R.2319
Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions related to the Protecting Patient Access to Cancer and Complex Therapies Act reintroduction Issues related to most-favored-nation and other foreign reference drug pricing policy Issues related to the Food and Drug Administration Issues regarding 340B program
Client expense: $380,000 · Firm income: —
Matched citations: H.R.946
Protecting Patient Access to Cancer and Complex Therapies Act
2026 · second_quarter · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act
2026 · second_quarter · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Women and Lung Cancer Research and Preventive Services Act of 2025
2026 · first_quarter · Firm: DAIICHI SANKYO INC
Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions related to the Protecting Patient Access to Cancer and Complex Therapies Act reintroduction Issues related to most-favored-nation and other foreign reference drug pricing policy Issues related to the Food and Drug Administration
Client expense: $130,000 · Firm income: —
Matched citations: H.R.2319
Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions related to the Protecting Patient Access to Cancer and Complex Therapies Act reintroduction Issues related to most-favored-nation and other foreign reference drug pricing policy Issues related to the Food and Drug Administration
Client expense: $130,000 · Firm income: —
Matched citations: H.R.946
Protecting Patient Access to Cancer and Complex Therapies Act
2026 · first_quarter · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act
2026 · first_quarter · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Women and Lung Cancer Research and Preventive Services Act of 2025
2025 · fourth_quarter · Firm: DAIICHI SANKYO INC
Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions related to the Protecting Patient Access to Cancer and Complex Therapies Act reintroduction
Client expense: $90,000 · Firm income: —
Matched citations: H.R.2319
Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions related to the Protecting Patient Access to Cancer and Complex Therapies Act reintroduction
Client expense: $90,000 · Firm income: —
Matched citations: H.R.946
Protecting Patient Access to Cancer and Complex Therapies Act
2025 · fourth_quarter · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act
2025 · fourth_quarter · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Women and Lung Cancer Research and Preventive Services Act of 2025
2025 · third_quarter · Firm: DAIICHI SANKYO INC
Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions related to the Protecting Patient Access to Cancer and Complex Therapies Act reintroduction
Client expense: $220,000 · Firm income: —
Matched citations: H.R.2319
Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions related to the Protecting Patient Access to Cancer and Complex Therapies Act reintroduction
Client expense: $220,000 · Firm income: —
Matched citations: H.R.946
Protecting Patient Access to Cancer and Complex Therapies Act
2025 · third_quarter · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act
2025 · third_quarter · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 946
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 946
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Client expense: — · Firm income: $50,000
Matched citations: S. 1862
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Client expense: — · Firm income: $50,000
Matched citations: S. 1862
Source: Senate LDA